A new perspective in the research of antibody drug conjugate
-
ABSTRACT
Antibody drug conjugate (ADC) combines the high specificity of monoclonal antibodies and the high activity of small molecule cytotoxic drugs through linkers to improve the targeting of tumor drugs and reduce the toxic side effects. Due to the advantages of clear targets, mature technology, and good selectivity, ADCs have shown excellent application prospects in hematological and solid tumor therapeutic fields. In this perspective, the selection of ADC-targeting antigens is described in the group of driver gene target antigens and non-driver gene target antigens to make more evident the importance of targeting antigens in advancing ADCs for tumor therapy. In the future, continued research and innovation in this field will help provide more effective, targeted, and personalized treatments for cancer patients, ultimately improving patients’ outcomes and quality of life. -
-
REFERENCES
[1] D'Alterio, C., Scala, S., Sozzi, G., et al. (2020). Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin. Cancer Biol. 60: 351-361. DOI: 10.1016/j.semcancer.2019.08.019. [2] Fu, Z., Li, S., Han, S., et al. (2022). Antibody drug conjugate: The "biological missile" for targeted cancer therapy. Signal Transduct. Target Ther. 7: 93. DOI: 10.1038/s41392-022-00947-7. [3] Jin, Y., Schladetsch, M.A., Huang, X., et al. (2022). Stepping forward in antibody-drug conjugate development. Pharmacol. Ther. 229: 107917. DOI: 10.1016/j.pharmthera.2021.107917. [4] Yu, J., Fang, T., Yun, C., et al. (2022). Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front. Mol. Biosci. 9: 847835. DOI: 10.3389/fmolb.2022.847835. [5] Najminejad, Z., Dehghani, F., Mirzaei, Y., et al. (2023). Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Mol. Ther. 31: 1874-1903. DOI: 10.1016/j.ymthe.2023.03.019. [6] Gillenwater, A.M., Cognetti, D., Johnson, J.M., et al. (2018). RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial. J. Clin. Oncol. 36: 6039-6039. DOI: 10.1200/jco.2018.36.15_suppl.6039. [7] Bardia, A., Hurvitz, S.A., Tolaney, S.M., et al. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med.384: 1529-1541. DOI: 10.1056/NEJMoa2028485. [8] Qiu, S., Zhang, J., Wang, Z., et al. (2023). Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochim. Biophys. Acta. Rev. Cancer 1878: 188902. DOI: 10.1016/j.bbcan.2023.188902. [9] Bouleftour, W., Sargos, P. and Magne, N. (2023). Nectin-4: A tumor cell target and status of inhibitor development. Curr. Oncol. Rep. 25: 181-188. DOI: 10.1007/s11912-023-01360-1. [10] Mao, J.J., Pillai, G.G., Andrade, C.J., et al. (2022). Integrative oncology: Addressing the global challenges of cancer prevention and treatment. CA Cancer J. Clin. 72: 144-164. DOI: 10.3322/caac.21706. -
ABOUT THIS ARTICLE
Cite this article:
Li Q., Jiang M., and Xu B. (2023). A new perspective in the research of antibody drug conjugate. The Innovation Medicine 1(2), 100018. https://doi.org/10.59717/j.xinn-med.2023.100018
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Li Q., Jiang M., and Xu B. (2023). A new perspective in the research of antibody drug conjugate. The Innovation Medicine 1(2), 100018. https://doi.org/10.59717/j.xinn-med.2023.100018
Format
Content
DownLoad:
-
Figure 1.
The processing mechanism of typical ADCs under multi-target antigens competition.
